<DOC>
	<DOCNO>NCT02003391</DOCNO>
	<brief_summary>The purpose study demonstrate superior intraocular pressure ( IOP ) control travoprost 0.004 % / timolol 0.5 % compare beta-blocker monotherapy participant open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Efficacy Travoprost/Timolol Uncontrolled Intraocular Pressure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Have clinical diagnosis either open angle glaucoma ocular hypertension . Currently betablocker monotherapy ( &gt; 30 day ) would benefit , opinion investigator , intraocular pressure ( lOP ) reduction . Have mean baseline lOP &gt; 18 mmHg &lt; 32 mmHg least one eye . Must able understand sign Informed Consent form . Other protocolspecified inclusion criterion may apply . Use medication exclude protocol . Diseases , illness , infection , ocular abnormality exclude protocol . Ocular surgery procedure exclude protocol . Bestcorrected visual acuity ( BCVA ) score bad 55 ETDRS letter ( equivalent 20/80 Snellen , 0.60 logMAR 0.25 decimal ) . Hypersensitivity prostaglandin analogue component study medication opinion investigator . Women childbearing potential pregnant , test positive pregnancy Screening visit , breastfeeding , agreement use adequate birth control method prevent pregnancy throughout study . Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Open Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
	<keyword>Intraocular Pressure</keyword>
</DOC>